EsoCheck and EsoGuard for the Detection of Barrett's Esophagus in Patients without Chronic Gastroesophageal Reflux Disease Symptoms
This clinical trial assesses the EsoCheck and EsoGuard (EC/EG) test to detect Barrett’s esophagus (BE) in patients without gastroesophageal reflux disease (GERD) symptoms and have some risk factors for developing it. BE is a condition in which the flat pink lining of the swallowing tube that connects the mouth to the stomach (the esophagus) becomes damaged by acid reflux. It is associated with an increased risk of developing esophageal cancer. The capsule balloon test called EC is a new Food and Drug Administration (FDA) approved method that is office based and examines the esophagus without using sedative medications or an endoscope. EG is a laboratory developed test that has an accuracy of 90% for BE in patients with GERD. EC/EG may help detect BE in patients without GERD symptoms.